{"id":"ly01005","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LY01005 is designed to inhibit key kinases or signaling molecules implicated in cancer cell growth and survival. The drug is being developed by Luye Pharma Group Ltd. and is currently in phase 3 clinical trials, though the precise molecular target and detailed mechanism require further clinical characterization.","oneSentence":"LY01005 is a small-molecule inhibitor that targets specific intracellular signaling pathways involved in cell proliferation and survival.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:19:52.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication under investigation in phase 3 trials)"}]},"trialDetails":[{"nctId":"NCT06385847","phase":"PHASE2","title":"To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-05","conditions":"Prostate Cancer","enrollment":60},{"nctId":"NCT05110170","phase":"PHASE3","title":"Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2020-10-15","conditions":"Breast Cancer","enrollment":188},{"nctId":"NCT05140512","phase":"PHASE1","title":"Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2021-02-04","conditions":"Prostate Cancer","enrollment":23},{"nctId":"NCT04563936","phase":"PHASE3","title":"Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX®","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2020-01-06","conditions":"Prostate Cancer","enrollment":290},{"nctId":"NCT03450109","phase":"PHASE1","title":"A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2017-12-22","conditions":"Cancer of Prostate","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Goserelin Acetate Sustained-Release Microspheres for Injection"],"phase":"phase_3","status":"active","brandName":"LY01005","genericName":"LY01005","companyName":"Luye Pharma Group Ltd.","companyId":"luye-pharma-group-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY01005 is a small-molecule inhibitor that targets specific intracellular signaling pathways involved in cell proliferation and survival. Used for Cancer (specific indication under investigation in phase 3 trials).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}